SCHEMBL126744

SCHEMBL126744

CCCCCCCCCC#C[O]

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN7 P35236 5/20 0.52
HMGCR P04035 5/20 0.52
RECQL P46063 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
TSHR P16473 1/20 0.44
THRB P10828 1/20 0.44
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
USP2 O75604 1/20 0.43
ALDH1A1 P00352 1/20 0.43
POLB P06746 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
ALOX12 P18054 1/20 0.43
BLM P54132 1/20 0.43
KMT2A Q03164 1/20 0.43
MCL1 Q07820 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
EPHX2 P34913 4/20 0.40
KCNH2 Q12809 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL128296 1.00 PTPN7 (0.52) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL448225 1.00 PTPN7 (0.52) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL130213 1.00 PTPN7 (0.52) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL170228 1.00 PTPN7 (0.52) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL448473 1.00 PTPN7 (0.52) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL128389 1.00
SCHEMBL131558 1.00 PTPN7 (0.52) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL453725 1.00 PTPN7 (0.52) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL448859 1.00 PTPN7 (0.52) PTPN7HMGCRRECQLTDP1TSHR
SCHEMBL18419984 1.00 PTPN7 (0.52) PTPN7HMGCRRECQLTDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0365149-A2 Leukotriene antagonist prodrugs SMITHKLINE BEECHAM CORPORATION (US) 1990-04-25 EP claimed
US-20240125678-A1 COMPOUND, CELLULAR VESICLE STAIN, AND METHOD FOR FLUORESCENT STAINING OF CELLULAR VESICLES NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (JP) 2024-04-18 US disclosed
WO-2024053316-A1 COMPOUND, EXTRACELLULAR VESICLE STAINING AGENT, AND FLUORESCENT STAINING METHOD FOR EXTRACELLULAR VESICLES 国立大学法人東海国立大学機構 2024-03-14 WO disclosed
EP-4286388-A1 COMPOUND, CELLULAR VESICLE STAIN, AND METHOD FOR FLUORESCENT STAINING OF CELLULAR VESICLES National University Corporation Tokai National Higher Education and Research System (JP) 2023-12-06 EP disclosed
EP-2883865-B1 Compound capable of binding S1P receptor and pharmaceutical use thereof ONO PHARMACEUTICAL CO (JP) 2019-09-25 EP disclosed
EP-2740724-B1 COMPOUND FOR TREATING CARTILAGE DISORDERS ONO PHARMACEUTICAL CO (JP) 2016-12-28 EP disclosed
EP-2657229-B1 BENZYLOXYPYRIMIDINE DERIVATIVE, AGRICULTURAL/HORTICULTURAL INSECTICIDE COMPRISING SAID DERIVATIVE AND METHOD FOR USING THE SAME NIHON NOHYAKU CO LTD (JP) 2016-03-30 EP disclosed
US-20160002247-A1 8-SUBSTITUTED IMIDAZOPYRIMIDINONE DERIVATIVE HAVING AUTOTAXIN INHIBITORY ACTIVITY THE UNIVERSITY OF TOKYO (JP) 2016-01-07 US disclosed
EP-1756271-B1 METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM 2,2-DISUBSTITUTED EPOXIDES CSIR (ZA) 2015-12-09 EP disclosed
EP-1753862-B1 METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM MESO-EPOXIDES CSIR (ZA) 2015-11-18 EP disclosed
US-5719176-A 2-amino-1,3-propanediol compound and immunosuppressant YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1998-02-17 US disclosed
US-5646273-A FOR USE IN OPTICAL DISKS MITSUI TOATSU CHEMICALS, INC. (JP) 1997-07-08 US disclosed
EP-0781827-A1 Liquid crystal mixture and liquid crystal device comprising the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1997-07-02 EP disclosed
US-5604229-A 2-amino-1,3-propanediol compound and immunosuppressant YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1997-02-18 US disclosed
EP-0709444-A1 Liquid crystal mixture and liquid crystal device comprising the same SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1996-05-01 EP disclosed
EP-0627406-A1 2-AMINO-1,3-PROPANEDIOL COMPOUND AND IMMUNOSUPPRESSANT YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1994-12-07 EP disclosed
EP-0619345-A1 Phthalocyanine compound and optical recording medium containing it MITSUI TOATSU CHEMICALS, Inc. (JP) 1994-10-12 EP disclosed
EP-0365149-A3 LEUKOTRIENE ANTAGONIST PRODRUGS SMITHKLINE BEECHAM CORPORATION (US) 1990-07-25 EP disclosed
EP-0365149-A2 Leukotriene antagonist prodrugs SMITHKLINE BEECHAM CORPORATION (US) 1990-04-25 EP disclosed
EP-0365149-A2 Leukotriene antagonist prodrugs SMITHKLINE BEECHAM CORPORATION (US) 1990-04-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240125678-A1 COMPOUND, CELLULAR VESICLE STAIN, AND METHOD FOR FLUORESCENT STAINING OF CELLULAR VESICLES EXOSC4, EXOSC5, EXOSC9 PTPN7 4035/4885HMGCR 3221/4885RECQL 1783/4885
US-20160002247-A1 8-SUBSTITUTED IMIDAZOPYRIMIDINONE DERIVATIVE HAVING AUTOTAXIN INHIBITORY ACTIVITY ENPP2, UACA, IAPP PTPN7 700/4885HMGCR 4576/4885RECQL 1513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.